Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceHeart & metabolic

Dihydroberberine

Dihydroberberine is a reduced berberine derivative that genuinely reaches the bloodstream better than berberine HCl — but the only human trial testing whether that translates into better glucose control found it did not. It is a promising delivery fix with essentially no clinical outcome data.

What the science says

  • Substantially higher plasma berberine exposure than berberine HCl Moderate evidence

    In a randomized crossover pilot, 100 mg and 200 mg dihydroberberine produced higher and more sustained plasma berberine concentrations over 4 hours than 500 mg berberine HCl, consistent with the rationale that dihydroberberine is absorbed and then oxidized back to berberine. Berberine HCl itself is notoriously poorly absorbed, with oral bioavailability under 1%, so the bar was low.

  • Better absorption did not produce better glucose control Limited evidence

    In that same crossover trial, neither 500 mg berberine nor 100-200 mg dihydroberberine improved the glucose or insulin response to a standardized meal versus placebo over the acute testing window. This is the crucial and under-reported finding: pharmacokinetic superiority has not been shown to convert into a metabolic advantage.

  • All efficacy claims are borrowed from berberine trials Limited evidence

    Berberine at 1,000-1,500 mg/day has umbrella-review support for lowering fasting glucose (roughly 0.5-0.9 mmol/L), HbA1c (about 0.5-0.7 percentage points) and LDL cholesterol in type 2 diabetes and metabolic syndrome. No trial of dihydroberberine has replicated any of these endpoints, and the assumed 5x potency conversion printed on labels is a marketing extrapolation, not a validated equivalence.

  • Fewer GI side effects is plausible but untested Limited evidence

    The main selling point beyond potency is less diarrhea and cramping, on the theory that less unabsorbed berberine reaches the colon. No trial has formally compared GI tolerability between forms in an adequately powered sample; the available crossover data included only a handful of participants.

Dosage & safety

Studied doseCommercial products (often sold as GlucoVantage) supply 100-200 mg dihydroberberine once or twice daily with meals, marketed as equivalent to 500-1,000 mg berberine HCl. The only human trial tested single doses of 100 mg and 200 mg. There is no established long-term dose. If your goal is documented metabolic benefit, standard berberine HCl at 500 mg two to three times daily with meals is what the outcome trials actually used.
SafetyHuman safety data are limited to short-term dosing in small samples; no long-term human toxicology exists. Berberine-class compounds inhibit CYP3A4, CYP2D6 and CYP2C9 and inhibit P-glycoprotein, so clinically important interactions are expected with statins, cyclosporine, macrolides, many antidepressants and anticoagulants — and better absorption theoretically increases that risk. Additive hypoglycemia with metformin, insulin or sulfonylureas. Contraindicated in pregnancy and breastfeeding and in neonates: berberine displaces bilirubin from albumin and has been linked to kernicterus risk. Not banned in sport. Do not treat this as an interchangeable swap for a prescribed glucose-lowering medication.

Scientific references

Where to buy

Toniiq, Dihydro Berberine 1000, 60 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Heart & metabolic